Valneva SE (VALN)

Market Cap	577.05M
Revenue (ttm)	175.56M
Net Income (ttm)	-12.68M
Shares Out	162.40M
EPS (ttm)	-0.09
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	12,728
Open	6.76
Previous Close	6.57
Day's Range	6.76 - 6.86
52-Week Range	3.62 - 9.50
Beta	1.29
Analysts	Strong Buy
Price Target	16.00 (+135.99%)
Earnings Date	May 6, 2025

About VALN

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; and IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by c...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: May 6, 2021
• Employees: 713
• Stock Exchange: NASDAQ
• Ticker Symbol: VALN
• Website: https://valneva.com

Financial Performance

In 2024, Valneva SE's revenue was 169.58 million, an increase of 10.32% compared to the previous year's 153.71 million. Losses were -12.25 million, -87.93% less than in 2023.

Financial numbers in EUR

Analyst Forecast

According to 2 analysts, the average rating for VALN stock is "Strong Buy." The 12-month stock price forecast is $16.0, which is an increase of 135.99% from the latest price.

Price Target

$16.0

(135.99% upside)

Analyst Consensus: Strong Buy